Who
Gilbert S. Omenn
Director
Company insider
Files Form 4 as: Director, Amesite; Director, Galectin Therapeutics; Director, Elicio Therapeutics; Director, Amesite; Director, Esperion Therapeutics; Director, Amgen; Director, Rohm & Haas Co; Director, OccuLogix.
In numbers
- Trades disclosed
- 202
- Buys
- 8
- Sells
- 7
- Bought
- $427K
- Sold
- $4.0M
- Companies
- 8
- Companies where not an officer
- 8
- First trade
- 1 Dec 2005
- Last trade
- 30 Sep 2026
- Last filed
- 2 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 30 Sep 2026filed 2 Oct 2026 | AMST Amesiteoption or derivative · Software | SEC FORM 4 Code A | —12,121 at $0.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | AMST Amesiteoption or derivative · Software | SEC FORM 4 Code A | —9,023 at $0.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | AMST Amesiteoption or derivative · Software | SEC FORM 4 Code A | —9,023 at $0.00 | filing |
| 31 Mar 2026filed 1 Apr 2026 | AMST Amesiteoption or derivative · Software | SEC FORM 4 Code A | —6,522 at $0.00 | filing |
| 31 Mar 2026filed 1 Apr 2026 | AMST Amesiteoption or derivative · Software | SEC FORM 4 Code A | —6,522 at $0.00 | filing |
| 7 Mar 2026filed 10 Mar 2026 | AMST AmesiteSoftware | SEC FORM 4 Code M | —41,322 | filing |
| 7 Mar 2026filed 10 Mar 2026 | AMST Amesiteoption or derivative · Software | SEC FORM 4 Code M | —41,322 at $0.00 | filing |
| 7 Mar 2026filed 10 Mar 2026 | AMST Amesiteoption or derivative · Software | SEC FORM 4 Code M | —41,322 at $0.00 | filing |
| 7 Mar 2026filed 10 Mar 2026 | AMST AmesiteSoftware | SEC FORM 4 Code M | —41,322 | filing |
| 6 Feb 2026filed 10 Feb 2026 | AMST Amesiteoption or derivative · Software | SEC FORM 4 Code A | —49,751 at $0.00 | filing |
| 6 Feb 2026filed 10 Feb 2026 | AMST Amesiteoption or derivative · Software | SEC FORM 4 Code A | —49,751 at $0.00 | filing |
| 16 Jan 2026filed 21 Jan 2026 | GALT Galectin Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 16 Jan 2026filed 21 Jan 2026 | GALT Galectin Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 31 Dec 2025filed 5 Jan 2026 | AMST Amesiteoption or derivative · Software | SEC FORM 4 Code A | —6,349 at $0.00 | filing |
| 31 Dec 2025filed 5 Jan 2026 | AMST Amesiteoption or derivative · Software | SEC FORM 4 Code A | —6,349 at $0.00 | filing |
| 30 Sep 2025filed 2 Oct 2025 | AMST Amesiteoption or derivative · Software | SEC FORM 4 Code A | —3,934 at $0.00 | filing |
| 30 Jun 2025filed 2 Jul 2025 | AMST Amesiteoption or derivative · Software | SEC FORM 4 Code A | —4,461 at $0.00 | filing |
| 31 Mar 2025filed 2 Apr 2025 | AMST Amesiteoption or derivative · Software | SEC FORM 4 Code A | —4,959 at $0.00 | filing |
| 7 Mar 2025filed 11 Mar 2025 | AMST Amesiteoption or derivative · Software | SEC FORM 4 Code A | —41,322 at $0.00 | filing |
| 7 Mar 2025filed 11 Mar 2025 | AMST AmesiteSoftware | SEC FORM 4 Code A | —41,322 | filing |
News
Amgen (AMGN) Sales Grew 10%, but Can Earnings Catch Up to the Price?AMGN · insidermonkey.com · 21 Oct 2026Amgen vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?AMGN · fool.com · 20 Oct 2026AMGEN TO PRESENT AT THE EUROPEAN SOCIETY OF MEDICAL ONCOLOGY CONGRESS 2026AMGN · prnewswire.com · 20 Oct 2026
0 headlines in the last 90 days name Gilbert S. Omenn; 3 articles from the last 14 days about the 3 companies they traded most, at most three about any one of them.